Skip to main content Accessibility help
×
Home

Controlled Evaluation of Nicotinamide Adenine Dinucleotide in the Treatment of Chronic Schizophrenic Patients

  • N. S. Kline (a1), G. L. Barclay (a2), J. O. Cole (a3), A. H. Esser (a4), H. Lehmann (a5) and J. R. Wittenborn (a6)...

Extract

On 30 March, 1966, at the Symposium “Enzymes in Mental Health” sponsored by the Carl Neuberg Society for International Scientific Relations, A. Hoffer (1) described the apparently successful treatment in 13 of 17 (acute and chronic) schizophrenic patients in 3 to 5 days by the daily oral use of 1 to 2 grams of nicotinamide adenine dinucleotide (NAD), better known as diphosphopyridinenucleotide (DPN). Widespread publicity given to this announcement attests to the need of more effective treatment for this illness. It also occasioned frequent and persistent inquiry from schizophrenic patients and their relatives as to the suitability of this treatment in their own instance. Rapid confirmation of the findings would justify widespread efforts to evaluate this preparation, whereas failure of confirmation would provide reasonable grounds for a more cautious approach to its use. The members of the Council of the American College of Neuropsycho-pharmacology decided that, as a group of impartial scientists, it would be appropriate for them to carry out such an investigation as rapidly as was compatible with adequate determination of the usefulness of the preparation.

Copyright

References

Hide All
1. Hoffer, A. (1966). As quoted in the New York Times, 31 March.
2. Hoffer, A. (1966). Personal communication.
3. Wittenborn, J. R. (1962). “The dimensions of psychosis.” J. nerv. ment. Dis., 134, 117128.
4. Hoffer, A., and Osmond, H. (1961). “A card sorting test helpful in making psychiatric diagnosis.” J. Neuropsychiat., 2, 306.
5. Overall, J. E., and Gorham, D. R. (1962). “The brief psychiatric rating scale.” Psychol. Reports, 10, 799812.
6. Chapple, E. D., Chamberlain, A. S., Esser, A. H., and Kline, N. S. (1963). “The measurement of activity patterns of schizophrenic patients.” J. nerv. ment. Dis., 136, 258267.
7. Hoffer, A. (1966). In a letter to Dr. N. S. Kline.
8. Gallant, D. M., Bishop, M. P., and Steele, C. A. (1966). “DPN (NAD-oxidized form): a preliminary evaluation in chronic schizophrenic patients.” Current Therapeutic Research, 8, 542.
9. O?Hollaren, P. (1961). “Diphosphopyridinc nucleotide in the prevention, diagnosis and treatment of problem drinkers.” West. J. Surg., Obst. and Gynec, 213215.
10. Gottlieb, J. S. (1966). Personal communication.

Controlled Evaluation of Nicotinamide Adenine Dinucleotide in the Treatment of Chronic Schizophrenic Patients

  • N. S. Kline (a1), G. L. Barclay (a2), J. O. Cole (a3), A. H. Esser (a4), H. Lehmann (a5) and J. R. Wittenborn (a6)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Controlled Evaluation of Nicotinamide Adenine Dinucleotide in the Treatment of Chronic Schizophrenic Patients

  • N. S. Kline (a1), G. L. Barclay (a2), J. O. Cole (a3), A. H. Esser (a4), H. Lehmann (a5) and J. R. Wittenborn (a6)...
Submit a response

eLetters

We encountered an error trying to retrieve eLetters for this article. Please try again or contact Customer Services

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *